Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4266)	10/9/1999 8:26:00 AM
From: Mad2	Read Replies (1) \| Respond to of 10293

Dan; sounds like the NEJM article is dead for now. techstocks.com If it were going to be published Hensley would know it, thus i take the lack of exuberance on the subject to mean the article was rejected. If one or the other of the new studies gets submitted it will still take some 6 months for a review and publication. In other words the hope for free publicity out of NEJM is pretty much gone for this cold season. Additionally it sounds like GUMM is still trying to establish (scientifically) that their stuff reduces the duration of the common cold and the facts will come from these studies that are pending. Dan I went looking for ZICAM in my local Walgreen's (it wasn't there) and I was suprised at the number of cold/allergy treatments the consumer has to choose from (poor Quigly, everyone has trampled the ground they paved). It's downright confusing. I even saw some nasel products (Symtech.....some blend of herb extracts, a saline product as well). In all the consumer has about 100 choices from pills to capusles to generic, lozenges and so on. If ZICAM were there i don't know what would make it move off the shelf.......too many other known brands or methods and ZICAM would be lost. Apart from shareholders and friends who read the threads on YAHOO, SI and perhaps Raging Bull who else is going to buy the stuff in any quanity. Mad2